• Molecular NameAmrinone
  • SynonymAmrinona [inn-spanish]; Amrinonum [inn-latin]; Inamrinone; Inamrinone lactate
  • Weight187.202
  • Drugbank_IDDB01427
  • ACS_NO60719-84-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.1
  • pka5.2
  • LogD (pH=7, predicted)-0.24
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.2
  • LogSw (predicted, AB/LogsW2.0)21.34
  • Sw (mg/ml) (predicted, ACD/Labs)11.16
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA68.01
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA type 3 pyridine phosphodiesterase inhibitor.
  • Absorption_value93.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability93.0
  • Protein binding42.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, Amrinone undergoes N-glycolation, N-acetatylation, and O-glucaronididation.
  • Half life2.94 h
  • ExcretionRenal (63%) and fecal (18%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most important cardiovascular adverse events are arrhythmia; hypotension. Nausea, vomiting, thrombocytopenia have also been reported.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A